At Immunetrics, we build predictive, biological models of drug targets and clinical trials. 


Our model simulations are able to inform our clients’ decisions at all stages of drug development; including pre-clinical targeting, trial designs, combination drug synergies, target patient populations, new indications, and FDA requests.



Modeling opens up an array of new opportunities and a paradigm shift in drug development: